secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIODESIX INC (BDSX)
CIK:        0001439725
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0000950170-23-060209
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biodesix Q3 2023: Lung diagnostic revenue up 34% YoY; net loss narrows 20%
--------------------------------------------------------------------------

- Total revenue $13.5M (+21% YoY); lung diagnostics $12.3M (+34% YoY); Biopharma Services $1.2M (+79% YoY).
- Lung diagnostic test volume >10,400 (+60% YoY); gross margin improved to 76% from 67%.
- Net loss $10.9M (-20% YoY); Adjusted EBITDA loss $5.4M (-40% YoY).
- FY 2023 revenue guidance lowered to $50-52M due to Medicare Advantage backlog removal; core business unchanged.
- Cash $19.8M at Sep 30; additional $10M draw from Perceptive term loan and final $12.2M private placement expected in Q4.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439725/000095017023060209/0000950170-23-060209-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439725/000095017023060209/bdsx-20231107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-060209

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer